PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1419100
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1419100
Respiratory Syncytial Virus Diagnostics Market size was valued at USD 931.89 Million in 2022, expanding at a CAGR of 9.63% from 2023 to 2030.
For Respiratory Syncytial Virus (RSV), rapid RSV antigen tests are the most often used test. They look for specific proteins from the RSV virus known as antigens in a fluid sample taken from your nose. RSV antigens cause the virus to be attacked by your immune system.
The main drivers propelling the market expansion are the rising rate of respiratory infections, the growing number of newborns, and the high demand for point-of-care facilities and in-vitro diagnostics. It is predicted that the number of respiratory infections will rise along with the global incidence of chronic illnesses. These infections are a major cause of death in newborns, although they can be prevented with prompt diagnosis and treatment. The worldwide market is being driven by the increasing incidence of respiratory syncytial virus diagnostic (RSV) sickness, especially in children under the age of two years.
Furthermore, due to the factors like rising healthcare infrastructure investments and parents' growing concern for their children's health, the market is growing favorably. The availability of diagnostic technologies and growing awareness of the great survival rates that follow early diagnosis are also having a favorable effect on the market's development. Positive government programs, such as reimbursement guidelines, awareness campaigns, and free diagnostics, among others, contribute to the market's expansion.
The Global Respiratory Syncytial Virus Diagnostics Market is segmented on the basis of Product, Method, End-User, and Region.
The market is divided into three categories based on Product: kits & reagents, instruments, and others. The kits & reagents segment dominates the market. Increasing demand for kits & reagents for RSV antigen tests is expected to boost the market growth.
The market is divided into seven categories based on Method: rapid antigen diagnostic test (RADTs), molecular diagnostics, chromatographic immunoassay, diagnostic imaging, gel microdroplets, flow cytometry, and others. The chromatographic immunoassay segment dominates the market and is likely to maintain its dominance during the forecast period. The rapid antigen diagnostic test (RADTs) has witnessed high demand in recent years due to COVID-19 concerns.
The market is divided into three categories based on End-User: hospitals, homecare & clinics, and others. The hospitals segment dominates the market and is likely to maintain its dominance during the forecast period. The homecare & clinics segment is expected to grow at a significant CAGR over the forecast period due to high need for laboratory research and testing.
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
RSV diagnostics market is highly competitive as the industry is seen as being extremely competitive. To improve their product portfolios and increase the attractiveness of their offerings, the major players employ strategies like mergers and acquisitions and the introduction of new products. The companies engage in developing new respiratory panels for better testing. Key player in the market includes Novartis AG, Abbott, La Roche, etc.
In November 2021, QIAGEN introduced and obtained CE-marking for the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test.
In September 2021, La Roche introduced a collection of three PCR diagnostic test panels based on molecular polymerase chain reaction technology. These panels are precisely designed to concurrently detect and distinguish various common respiratory pathogens.
The scope of this report covers the market by its major segments, which include as follows: